Renaissance Technologies LLC Has $1.01 Million Stock Holdings in Sensei Biotherapeutics, Inc. $FTH

Renaissance Technologies LLC lifted its position in Sensei Biotherapeutics, Inc. (NASDAQ:FTH) by 178.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 32,041 shares of the company’s stock after purchasing an additional 20,525 shares during the quarter. Renaissance Technologies LLC’s holdings in Sensei Biotherapeutics were worth $1,010,000 at the end of the most recent reporting period.

Wall Street Analyst Weigh In

FTH has been the subject of several analyst reports. BTIG Research reissued a “buy” rating and set a $55.00 price target on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Loop Capital set a $50.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, May 28th. Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. JonesTrading initiated coverage on Sensei Biotherapeutics in a report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Sensei Biotherapeutics in a report on Thursday, June 4th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Sensei Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $54.90.

Insiders Place Their Bets

In other news, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the sale, the insider owned 130,142 shares in the company, valued at $2,605,442.84. The trade was a 16.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were acquired at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the transaction, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is currently owned by corporate insiders.

Sensei Biotherapeutics Price Performance

Shares of FTH stock opened at $32.34 on Friday. Sensei Biotherapeutics, Inc. has a 1 year low of $7.21 and a 1 year high of $37.90. The business’s 50 day moving average is $26.65. The firm has a market capitalization of $835.67 million, a price-to-earnings ratio of -0.23 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter. Equities research analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current year.

Sensei Biotherapeutics Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.